在接受Rituximab治疗的患者的持续COVID-19肺炎
Karen Clarke1, Sathyabama Naidu1, Claire Wan2
1Division of Hospital Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Journal of investigative medicine high impact case reports
|January 6, 2026
概括
持久性SARS-CoV-2感染的免疫抑制患者可能会患上严重的肺炎. 一种多模式治疗方法,包括抗病毒药物和免疫调节剂,在一个具有挑战性的病例中有效地解决了症状.
科学领域:
- 免疫学 免疫学 免疫学
- 传染性疾病 传染性疾病
- 肺部病理学 肺部病理学
背景情况:
- 免疫抑制个体面临SARS-CoV-2的更高风险,包括持续感染和炎症.
- 治疗慢性炎症性脱髓性多神经病症的利图西马布治疗可以加剧SARS-CoV-2并发症.
研究的目的:
- 要突出一种持续的SARS-CoV-2感染病例,在免疫抑制患者中呈现为组织性肺炎.
- 为了说明诊断挑战和有效的多式联络治疗严重的COVID-19在免疫受损的主机.
主要方法:
- 一个52岁的男性接受Rituximab治疗,患有复发性肺炎的病例报告.
- 诊断工作包括连续的鼻PCR和支气管支气管洗.
- 治疗包括尼尔马特雷尔维尔/里托纳维尔,巴里西提尼布,IVIG和IV甲基prednisolone的组合.
主要成果:
- 患者经历了三个月的复发性肺炎,最初被误诊.
- 尽管鼻抽样呈阴性,但SARS-CoV-2通过支气管支气管洗得到证实.
- 多模式治疗导致了迅速和持续的临床改善.
结论:
- 在免疫抑制患者的不明原因的组织性肺炎中,应考虑持久性COVID-19.
- 多式疗法有效治疗严重,持久的SARS-CoV-2感染在免疫受损的个体.
相关概念视频
01:28Pneumonia IV: Management
749
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
749
01:30Pneumonia III: Complications and Assessment
775
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
775
01:30Pneumonia V: Nursing management and Prevention
3.4K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.4K
01:29Pneumonia II: Pathophysiology
2.5K
The pathophysiology of pneumonia involves the following steps:
2.5K
01:30Pneumonia I: Introduction
717
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
717
01:21Acute Respiratory Failure-II
1.0K
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
1.0K